Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Détails

ID Serval
serval:BIB_FA1EDD167A59
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).
Périodique
Haematologica
Auteur(s)
Averbuch D., Cordonnier C., Livermore D.M., Mikulska M., Orasch C., Viscoli C., Gyssens I.C., Kern W.V., Klyasova G., Marchetti O., Engelhard D., Akova M., ECIL4 a joint venture of EBMT EORTC ICHS ESGICH/ESCMID , ELN 
Contributeur(s)
ECIL4 a joint venture of EBMT EORTC ICHS ESGICH/ESCMID , ELN 
ISSN
1592-8721 (Electronic)
ISSN-L
0390-6078
Statut éditorial
Publié
Date de publication
2013
Volume
98
Numéro
12
Pages
1836-1847
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish. pdf type: guideline article
Résumé
The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4(th) European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists.
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/01/2014 17:22
Dernière modification de la notice
09/05/2019 3:46
Données d'usage